SRPT Sarepta Therapeutics Inc

Price (delayed)

$66.79

Market cap

$5.33B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.94

Enterprise value

$5B

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going ...

Highlights
SRPT's gross profit is up by 43% year-on-year and by 4.9% since the previous quarter
The revenue rose by 41% YoY and by 6% QoQ
Sarepta Therapeutics's quick ratio has decreased by 31% YoY but it has increased by 3.9% from the previous quarter
SRPT's debt has surged by 53% year-on-year and by 7% since the previous quarter
The company's equity has shrunk by 53% YoY and by 30% QoQ

Key stats

What are the main financial stats of SRPT
Market
Shares outstanding
79.77M
Market cap
$5.33B
Enterprise value
$5B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
9.91
Price to sales (P/S)
9.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.72
Earnings
Revenue
$573.36M
EBIT
-$703.08M
EBITDA
-$660.87M
Free cash flow
-$794.93M
Per share
EPS
-$8.94
Free cash flow per share
-$10
Book value per share
$6.74
Revenue per share
$7.22
TBVPS
$34.63
Balance sheet
Total assets
$2.77B
Total liabilities
$2.23B
Debt
$1.15B
Equity
$535.45M
Working capital
$1.91B
Liquidity
Debt to equity
2.15
Current ratio
6.23
Quick ratio
5.09
Net debt/EBITDA
0.5
Margins
EBITDA margin
-115.3%
Gross margin
87.2%
Net margin
-122.8%
Operating margin
-104.3%
Efficiency
Return on assets
-24.7%
Return on equity
-87.1%
Return on invested capital
-37.5%
Return on capital employed
-29.3%
Return on sales
-122.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SRPT stock price

How has the Sarepta Therapeutics stock price performed over time
Intraday
-3.36%
1 week
-0.39%
1 month
-14.77%
1 year
-58.69%
YTD
-60.82%
QTD
-14.09%

Financial performance

How have Sarepta Therapeutics's revenue and profit performed over time
Revenue
$573.36M
Gross profit
$500.25M
Operating income
-$598M
Net income
-$703.89M
Gross margin
87.2%
Net margin
-122.8%
SRPT's operating margin is up by 43% YoY
SRPT's gross profit is up by 43% year-on-year and by 4.9% since the previous quarter
The revenue rose by 41% YoY and by 6% QoQ
The net income has decreased by 27% QoQ and by 7% YoY

Growth

What is Sarepta Therapeutics's growth rate over time

Valuation

What is Sarepta Therapeutics stock price valuation
P/E
N/A
P/B
9.91
P/S
9.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.72
The EPS has contracted by 26% from the previous quarter
The company's equity has shrunk by 53% YoY and by 30% QoQ
SRPT's P/B is 25% below its last 4 quarters average of 13.3 but 14% above its 5-year quarterly average of 8.7
The P/S is 94% less than the 5-year quarterly average of 162.7 and 56% less than the last 4 quarters average of 21.2
The revenue rose by 41% YoY and by 6% QoQ

Efficiency

How efficient is Sarepta Therapeutics business performance
The return on equity has dropped by 51% since the previous quarter and by 35% year-on-year
The ROA has decreased by 29% from the previous quarter but it has increased by 23% YoY
The ROS has grown by 24% YoY but it has contracted by 20% from the previous quarter
Sarepta Therapeutics's ROIC has increased by 21% YoY but it has decreased by 20% from the previous quarter

Dividends

What is SRPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SRPT.

Financial health

How did Sarepta Therapeutics financials performed over time
The total assets is 24% more than the total liabilities
Sarepta Therapeutics's quick ratio has decreased by 31% YoY but it has increased by 3.9% from the previous quarter
The company's current ratio fell by 25% YoY but it rose by 4.4% QoQ
SRPT's debt is 115% greater than its equity
SRPT's debt has surged by 53% year-on-year and by 7% since the previous quarter
The company's equity has shrunk by 53% YoY and by 30% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.